Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma

被引：13

作者：

Hoering, Elisabeth ^{[1
,2
,3
,4
]}

Montraveta, Arnau ^{[4
]}

Heine, Simon ^{[1
,2
]}

Kleih, Markus ^{[1
,2
]}

Schaaf, Lea ^{[1
,2
]}

Voehringer, Matthias C. ^{[3
]}

Esteve-Arenys, Anna ^{[4
]}

Roue, Gael ^{[4
]}

Colomer, Dolors ^{[4
]}

Campo, Elias ^{[4
]}

Ott, German ^{[5
]}

Aulitzky, Walter E. ^{[3
]}

van der Kuip, Heiko ^{[1
,2
]}

机构：

[1] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Auerbachstr 112, D-70376 Stuttgart, Germany

[2] Univ Tubingen, Tubingen, Germany

[3] Robert Bosch Krankenhaus, Dept Haematol & Oncol, Stuttgart, Germany

[4] Univ Barcelona, IDIBAPS, Haematopathol Unit, Hosp Clin, Barcelona, Spain

[5] Robert Bosch Krankenhaus, Dept Clin Pathol, Stuttgart, Germany

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2017年 / 177卷 / 04期

关键词：

mantle cell lymphoma; NOXA; MCL1; Dinaciclib; FASNi; DEPENDENT KINASE INHIBITOR; DINACICLIB; BORTEZOMIB; RESPONSES; LEUKEMIA;

D O I：

10.1111/bjh.14571

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Imbalances in the composition of BCL2 family proteins contribute to tumourigenesis and therapy resistance of mantle cell lymphoma (MCL), making these proteins attractive therapy targets. We studied the efficiency of dual targeting the NOXA/MCL1 axis by combining fatty acid synthase inhibitors (NOXA stabilization) with the CDK inhibitor Dinaciclib (MCL1 reduction). This combination synergistically induced apoptosis in cell lines and primary MCL cells and led to almost complete inhibition of tumour progression in a mouse model. Apoptosis was NOXA-dependent and correlated with the NOXA/MCL1 ratio, highlighting the importance of the NOXA/MCL1 balance for effective cell death induction in MCL.

引用

页码：557 / 561

页数：5

共 50 条

[21] MARCH5-dependent degradation of MCL1/NOXA complexes defines susceptibility to antimitotic drug treatment
Manuel D. Haschka
Gerlinde Karbon
Claudia Soratroi
Katelyn L. O’Neill
Xu Luo
Andreas Villunger
Cell Death & Differentiation, 2020, 27 : 2297 - 2312
[22] MARCH5-dependent degradation of MCL1/NOXA complexes defines susceptibility to antimitotic drug treatment
Haschka, Manuel D.
Karbon, Gerlinde
Soratroi, Claudia
O'Neill, Katelyn L.
Luo, Xu
Villunger, Andreas
CELL DEATH AND DIFFERENTIATION, 2020, 27 (08): : 2297 - 2312
[23] Targeting MCL1 in NPM1-mutant AML
Qutob, Haitham
Abdul-Aziz, Amina
Proudfoot, Amy
Grundy, Martin
Russell, Nigel H.
Pallis, Monica
Seedhouse, Claire H.
CANCER RESEARCH, 2014, 74 (19)
[24] Targeting MCL1, Companies Aim to Unblock Apoptosis
Dolgin, Elie
CANCER DISCOVERY, 2019, 9 (05) : 572 - 572
[25] The splenic form of mantle cell lymphoma (MCL).
Angelopoulou, MK
Siakantaris, MP
Kontopidou, F
Rassidakis, G
Voskaridou, E
Kittas, C
Pangalis, GA
BLOOD, 1998, 92 (10) : 241A - 241A
[26] Dual Inhibition of MCL1 and BCL2 in Lymphoma Using Tumor Targeted Nanoparticles
Bala, Neeta Bala
Manzari, Mandana Taghizadeh
Ferreira, Mariana Da Silva
Asgari, Zahra
Hagen, Connor
Seshan, Venkatraman
de Stanchina, Elisa
Manova-Todorova, Katia
Heller, Daniel
Younes, Anas
BLOOD, 2019, 134
[27] MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-XL expression
Yasuda, Yuto
Ozasa, Hiroaki
Kim, Young Hak
Yamazoe, Masatoshi
Ajimizu, Hitomi
Funazo, Tomoko Yamamoto
Nomizo, Takashi
Tsuji, Takahiro
Yoshida, Hironori
Sakamori, Yuichi
Nakajima, Naoki
Menju, Toshi
Yoshizawa, Akihiko
Date, Hiroshi
Hirai, Toyohiro
CELL DEATH & DISEASE, 2020, 11 (03)
[28] MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-XL expression
Yuto Yasuda
Hiroaki Ozasa
Young Hak Kim
Masatoshi Yamazoe
Hitomi Ajimizu
Tomoko Yamamoto Funazo
Takashi Nomizo
Takahiro Tsuji
Hironori Yoshida
Yuichi Sakamori
Naoki Nakajima
Toshi Menju
Akihiko Yoshizawa
Hiroshi Date
Toyohiro Hirai
Cell Death & Disease, 11
[29] Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma
Prukova, Dana
Andera, Ladislav
Nahacka, Zuzana
Karolova, Jana
Svaton, Michael
Klanova, Magdalena
Havranek, Ondrej
Soukup, Jan
Svobodova, Karla
Zemanova, Zuzana
Tuskova, Diana
Pokorna, Eva
Helman, Karel
Forsterova, Kristina
Pacheco-Blanco, Mariana
Vockova, Petra
Berkova, Adela
Fronkova, Eva
Trneny, Marek
Klener, Pavel
CLINICAL CANCER RESEARCH, 2019, 25 (14) : 4455 - 4465
[30] From Inhibition to Degradation: Targeting the Antiapoptotic Protein Myeloid Cell Leukemia 1 (MCL1)
Papatzimas, James W.
Gorobets, Evgueni
Maity, Ranjan
Muniyat, Mir Ishruna
MacCallum, Justin L.
Ner, Paola
Bahlis, Nizar J.
Derksen, Darren J.
JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (11) : 5522 - 5540

← 1 2 3 4 5 →